期刊文献+

真核重组表达质粒pTT5-CTP-PTEN的构建及其在HEK 293-6E细胞中的表达

Construction of recombinant eukaryotic expression vector pTT5-CTP-PTEN and its expression in HEK 293-6E cells
原文传递
导出
摘要 目的构建真核重组表达质粒pTT5-CTP-PTEN,并在HEK 293-6E细胞中进行表达。方法合成融合基因CTP-PTEN,定向克隆至真核表达载体pTT5中,构建重组表达质粒pTT5-CTP-PTEN,转化感受态E.coli DH5α,提取质粒,进行双酶切及测序鉴定。在Lipofectamine 2000的介导下,将鉴定正确的重组表达质粒转染至HEK 293-6E细胞,Western blot法检测细胞中融合蛋白CTP-PTEN的表达。结果经双酶切及测序鉴定,证明重组表达质粒pTT5-CTPPTEN构建正确。转染48 h后,HEK 293-6E细胞中可见相对分子质量约49 700的CTP-PTEN融合蛋白条带。结论成功构建了重组质粒pTT5-CTP-PTEN,并于HEK 293-6E细胞中表达了CTP-PTEN融合蛋白。 Objective To construct recombinant eukaryotic expression vector pTT5-CTP-PTEN and express in HEK 293-6E cells. Methods Fusion gene CTP-PTEN was synthesized and cloned into eukaryotic expression vector pTT5. The constructed recombinant plasmid pTT5-CTP-PTEN was transformed to E.coli DH5α. The recombinant plasmid was extracted,identified by restriction enzyme digestion and DNA sequencing, and transfected to HEK 293-6E cells in mediation of Lipofectamine 2000. The expressed fusion protein was identified by Western blot. Results Restriction analysis and sequencing proved that recombinant plasmid pTT5-CTP-PTEN was constructed correctly. CTP-PTEN fusion protein band,with a relative molecular mass of about 49 700, was observed in HEK 293-6E cells 48 h after transfection. Conclusion Recombinant plasmid pTT5-CTP-PTEN was successfully constructed, and CTP-PTEN fusion protein was successfully expressed in HEK 293-6E cells.
出处 《中国生物制品学杂志》 CAS CSCD 2017年第4期377-380,共4页 Chinese Journal of Biologicals
基金 成都市医学科研课题(2014001) 成都学院校青年基金项目(2014XJZ08) 成都大学附属医院院内课题(2014016)
关键词 PTEN基因 胞浆转导肽 基因表达 真核细胞 HEK 293-6E细胞 PTEN gene Cytoplasmic transduction peptide(CTP) Gene expression Eukaryotic cells HEK 293-6E cells
  • 相关文献

参考文献1

二级参考文献31

  • 1Te HS and Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010, 14:1-21.
  • 2Raney AK, Hamatake RK and Hong Z. Agents in clinical development for the treatment of chronic hepatitis B. Expert Opin Investig Drugs 2003, 12: 1281-1295.
  • 3Lohr HF, Krug S, Herr W, Weyer S, Schlaak J, W61fel T and Gerken G, et al. Quantitative and ftmctional analysis of core-specific T-helper cell and CTL activities in acute and chronic hepatitis B. Liver 1998, 18: 405-413.
  • 4Webster G J, Reignat S, Maini MK, Whalley SA, Ogg GS, King A and Brown D, et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 2000, 32:1117-1124.
  • 5Yang SH, Lee CG and Park SH. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther 2006, 13:1110-1117.
  • 6Bertoletti A, Maini M and Williams R. Role of hepatitis B virus specific cytotoxic T cells in liver damage and viral control. Antiviral Res 2003, 60: 61-66.
  • 7Momburg F and Tan P. Tapasin--the keystone of the loading complex optimizing peptide binding by MHC class I molecules in the endoplasmic reticulum. Mol Immunol 2002, 39: 217-233.
  • 8Grandea AG, III and Van Kaer L. Tapasin: an ER chaperone that controls MHC class I assembly with peptide. Trends Immuno12001, 22: 194-199.
  • 9Brooke P, Garbi N, Momburg F and Himmerling GJ. HLA-DM, HLA-DO and tapasin: functional similarities and differences. Curr Opin Immunol 2002, 14: 22-29.
  • 10Lehner P J, Surman MJ and Cresswell P. Soluble tapasin restores MHC class I expression and fimction in the tapasin-negative cell line .220. Immunity 1998, 8: 221-231.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部